Research Use Only — Not for Human or Veterinary Use.
Sign in
‹ Library

CJC-1295 DAC

Growth Hormone SecretagogueResearch Use Only

Also known as: CJC-1295 with DAC, Drug Affinity Complex GRF, DAC:GRF

CJC-1295 DAC is a long-acting analog of growth-hormone-releasing hormone (GHRH) modified with a Drug Affinity Complex that binds albumin to extend its circulating half-life. It is commonly referenced in research literature examining growth-hormone and IGF-1 axis stimulation. This entry is educational and research-use-only, not medical advice.

Typical range (research)
Commonly referenced in literature around 1–2 mg per week (research reference only)
Half-life
~6–8 days (extended by DAC albumin binding)
Route
Subcutaneous (research)
Common use
Studied as a GHRH analog for sustained stimulation of endogenous growth-hormone release
Common vial sizes
2 mg · 5 mg
Storage
Lyophilized powder stored refrigerated or frozen and protected from light; reconstituted solution refrigerated (2–8 °C) and used within several weeks
Stacking notes
Commonly discussed alongside a GHRP such as Ipamorelin to combine GHRH and secretagogue pathways

Reported side effects

Injection-site reactionWater retention reported anecdotallyHead or facial flushing reported anecdotallyTingling or numbness reported anecdotally
Regulatory note: Not an approved therapeutic; sold for research purposes only
Calculate a dose →

Dose figures are ranges commonly referenced in research literature, not recommendations or medical advice. Not for human or veterinary use. Consult a licensed physician.